FRATES JAMES M (Chief Financial Officer) sold 4.6% of their position (7.91K shares) of AMYLYX PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $114.9K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/4/2026ACC: 0001193125-26-091438
Officer· Chief Financial Officer
Since Jan 2022
-7.91K
Net shares
Net seller
$114.9K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
7.91K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−7.91K
Price / share
$14.52
Trade value
$114.85K
% of position
4.6%
3/2/2026
173.55K→165.64K
Total
Net shares
−7.91K
Net value
-$114.85K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/2/2026 | S · Sale | −7.91K | $14.52 | $114.85K | 4.6% | 173.55K | 165.64K |
| Total | −7.91K | -$114.85K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned11.07K
Common Stock
IndirectShares owned100K
Common Stock
IndirectShares owned15.46K
Total
126.53K indirect126.53K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 11.07K | Indirect |
| Common Stock | 100K | Indirect |
| Common Stock | 15.46K | Indirect |
| Total | 126.53K | 126.53K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported